The Major Vault Protein (MVP), a New Multidrug Resistance Associated Protein, is Frequently Expressed in Multiple Myeloma

References

• Kyle R. Diagnosis and management of multiple myeloma and related disorders. Pr Hematol 1986; 14: 257
   PubMedGoogle Scholar
• Durie B, Salmon S. The current status and future prospects of treatment of multiple myeloma. Clin Haematol 1982; 11: 181
   PubMedGoogle Scholar
• Dalton W, Grogan T, Rybski J, Scheper R, Richter L, Kailey J, Broxtennan H, Pinedo H, Salmon S. Immunohistochemi-cal detection and quatitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73: 747
   PubMed Web of Science ®Google Scholar
• Salmon S, Grogan T, Miller T, Scheper R, Dalton W. Prediction of doxorubicin resistance in vitro in myeloma. lymphoma, and breast cancer by p-glycoprotein staining. Journal of the National Cancer Institute 1989; 81: 696
   PubMed Web of Science ®Google Scholar
• Grogan T, Spier C, Salmon S, Matzner M, Rybski J, Wein-Stein R, Scheper R, Dalton W. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490
   PubMed Web of Science ®Google Scholar
• Salmon S, Dalton W, Grogan T, Plezia P, Lehnert M, Roe D, Miller T. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 778: 44
   Google Scholar
• Sonneveld P, Dune B, Lokhorst H, Marie J-P, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K. Modulation of multi-drug-resistant multiple myeloma by cyclosporin. The Lancet 1992; 340: 255
   PubMed Web of Science ®Google Scholar
• Cole S, Bhardwaj G, Gerlach J, Mackie J, Grant C, Almquist K, Stewart A, Kurz E, Duncan A, Deeley R. Overexpression of a transporter gene in multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650
   PubMed Web of Science ®Google Scholar
• Flens M, Zaman G, Van Der Valk P, Izquierdo M, Schroeijers A, Scheffer G, Van Der Groep P, De Haas M, Meijer C, Scheper R. Tissue distribution of the multidrug resistance protein. American Journal of Pathology 1996; 148: 1237
   PubMed Web of Science ®Google Scholar
• Grant C, Valdimarsson G, Hipfner D, Almquist K, Cole S, Deeley R. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Research 1994; 54: 357
   PubMed Web of Science ®Google Scholar
• Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Van Heijningen TH, Van Kalken CK, Slovak ML, De Vries EG, Van Der Valk P, Meijer CJ, Pinedo HM. Overexpression of a Mr 100,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research 1993; 53: 1475
   PubMed Web of Science ®Google Scholar
• Izquierdo M, Scheffer G, Flens M, Giaccone G, Broxterman H, Meijer C, Van Der Valk P, Scheper R. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. American Journal of Pathology 1996; 148: 877
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nature Medicine 1995; 1: 578
   PubMed Web of Science ®Google Scholar
• Schuurhuis G, Broxterman H, Cervantes A, Van Heijningen T, De Lange J, Baak J, Pinedo H, Lankelma J. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. Journal of the National Cancer Institute 1989; 81: 1887
   PubMed Web of Science ®Google Scholar
• List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464
   PubMed Web of Science ®Google Scholar
• Izquierdo MA, Van Der Zee AG, Vermorken JB, Van Der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJ, De Vries EG, Scheper RJ. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. Journal of the National Cancer Institute 1995; 87: 1230
   PubMed Web of Science ®Google Scholar
• Den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schauh G, Henze G, Creutzig U, Scheper RJ, Veerman AJP. Relationship between major vault protein/lung resistance protein, Multidrug resistance-associated protein, p-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092
   PubMed Web of Science ®Google Scholar
• Dalton W, Drurie B, Alberts D, Gerlach J, Cress A. Characterization of a new drug resistant human myeloma cell line that expresses p-glycoprotein. Cancer Research 1986; 46: 5125
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resis-tant human multiple myeloma cell line. Cancer Research 1991; 51: 995
   PubMed Web of Science ®Google Scholar
• Futscher B, Abbaszadegen M, Domann F, Dalton W. Analysis of MRP mRNA in mitoxantrone-selected. multidrug resistant human tumor cells. Biochem Pharrnacol 1994; 47: 1601
   PubMed Web of Science ®Google Scholar
• Abbaszadegan M, Foley N, Gleason-Guzman M, Dalton W. Resistance to the chemosensitizer verapamil in a multi-drug resistant (MDR) human multiple myeloma cell line. International Journal of Cancer 1996; 66: 506
   PubMed Web of Science ®Google Scholar
• Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S. Optimization of immunocytochemical P-giycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Laboratory Investigation 1990; 63: 815
   PubMed Web of Science ®Google Scholar
• Grogan T, Rangel C, Rimsza L, . Kinetic-mode automated double labeled immunohistochemistry and in situ hybridization in diagnostic pathology. Advances in Pathology and Laboratory Medicine, R Weinstein, et al. Mosby, New York 1995; Vol. 8
   Google Scholar
• Bhalla K, Hindenburg A, Taub R, Grant S. Isolation and characterization of an anthracycline-resistant human leuke-mic cell line. Cancer Research 1985; 45: 3657
   PubMed Web of Science ®Google Scholar
• Wyler B, Shao Y, Schneider E, Cianfriglia M, Scheper RJ, Frey BM, Gieseler F, Schmid L, Twentyman P, Lehnert M. Intermittent exposure to doxorubicin in vitro selects for mul-tifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. British Journal of Haematology 1996; 97: 65
   Web of Science ®Google Scholar
• Abbaszadegan M, Futscher B, Klimecki W, List A, Dalton W. Analysis of multidrug resistance-associated proteim (MRP) messenger RNA in normal and malignant hematopoi-etic cells. Cancer Research 1994; 54: 4676
   PubMed Web of Science ®Google Scholar
• Izquierdo M, Shoemaker R, Flens M, Scheffer G, Wu L, Prather T, Scheper R. Overlapping phenotypes of multidrug resistance among panels of human cancer cell Iines. International Journal of Cancer 1996; 65: 230
   PubMed Web of Science ®Google Scholar
• Wu L, Smythe A, Stinson S, et al. Multidrug resistant pheno-type of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Research 1992; 52: 3029
   PubMed Web of Science ®Google Scholar
• Izquierdo M, Scheffer G, Flens M, Shoemaker R, Rome L, Scheper R. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cyto-technology 1996; 19: 191
   Google Scholar
• Izquierdo M, Neefjes J, Mathari A, Flens M, Scheffer G, Scheper R. Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. British Journal of Cancer 1961; 74: 1996
   Google Scholar
• Goasguen J, Lamy T, Bergeron C, Ly Sunaram B, Mordelet E, Gone G, Dossot J, Le Gall E, Grosbois B, Le Prise P, Fauchet R. Multifactorial drug-resistance phenomenon in acute leukemias: impact of P170-MDR1, LRP56 protein, glutathione-transferases and metallothionein systems on clinical outcome. Leukemia and Lymphoma 1996; 23: 567
   PubMed Web of Science ®Google Scholar
• Danks M, Schmidt C, Cirtain M, Suttle D, Beck W. Altered catalytic activity of an DNA cleavage by DNA topoisomerase Il from human leukemic cells seiected for resistance to VM-26. Biochemistry 1988; 27: 8861
   PubMed Web of Science ®Google Scholar
• Raaijmakers HGP, IzquierdÖ MA, Lokhorst HM, De Leeuw C, Belien JAM, Bloem AC, Dekker AW, Scheper RJ, Sonn-Eveld P. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, Borrego D, Carnero M, Casanova F, Jimenez R, Portero JA, Orfao A. A new staging system for multiple myeloma based on the number of S-phase. plasma cells Blood 1995; 85: 448
   PubMed Web of Science ®Google Scholar